Ganoderma lucidum polysaccharides attenuates pressure-overload-induced pathological cardiac hypertrophy

Pathological cardiac hypertrophy is an important risk factor for cardiovascular disease. However, drug therapies that can reverse the maladaptive process and restore heart function are limited. polysaccharides (GLPs) are one of the main active components of ( ), and they have various pharmacological...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 14; p. 1127123
Main Authors Zhen, Changlin, Wu, Xunxun, Zhang, Jing, Liu, Dan, Li, Guoli, Yan, Yongbo, He, Xiuzhen, Miao, Jiawei, Song, Hongxia, Yan, Yifan, Zhang, Yonghui
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 23.03.2023
Subjects
cardiac hypertrophy
GLPs
heart function
PGC-1α
Pharmacology
PPARγ
GLPs
PGC-1α
cardiac hypertrophy
heart function
PPARγ
Online AccessGet full text

Cover

More Information
Summary:Pathological cardiac hypertrophy is an important risk factor for cardiovascular disease. However, drug therapies that can reverse the maladaptive process and restore heart function are limited. polysaccharides (GLPs) are one of the main active components of ( ), and they have various pharmacological effects. GLPs have been used as Chinese medicine prescriptions for clinical treatment. In this study, cardiac hypertrophy was induced by transverse aortic constriction (TAC) in mice. We found that GLPs ameliorate Ang II-induced cardiomyocyte hypertrophy and attenuate pressure overload-induced cardiac hypertrophy . Further research indicated that GLPs attenuated the mRNA levels of hypertrophic and fibrotic markers to inhibit cardiac hypertrophy through the PPARγ/PGC-1α pathway. Overall, these results indicate that GLPs inhibit cardiac hypertrophy through downregulating key genes for hypertrophy and fibrosis and attenuate pressure overload-induced pathological cardiac hypertrophy by activating PPARγ. This study provides important theoretical support for the potential of using GLPs to treat pathological myocardial hypertrophy and heart failure.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology
Reviewed by: Yafeng Li, The Fifth Hospital of Shanxi Medical University, China
Edited by: Hai-dong Guo, Shanghai University of Traditional Chinese Medicine, China
These authors have contributed equally to this work
Xichun Pan, Army Medical University, China
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2023.1127123